Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344708 | 0.86 | LMNA (0.34) | — | |
| SCHEMBL23344701 | 0.81 | OPRM1 (0.30) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23345253 | 0.76 | OPRM1 (0.30) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12971961 | 0.75 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL4729116 | 0.74 | — | — | |
| SCHEMBL18718125 | 0.74 | — | — | |
| SCHEMBL11887349 | 0.74 | — | — | |
| SCHEMBL579902 | 0.73 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL15187736 | 0.73 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL23344709 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIGEL PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210070735-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. | 2021-03-11 | — | — | US | disclosed |
| WO-2001035938-A2 | PHARMACOLOGICALLY ACTIVE TETRAHYDRO THIOPYRAN-4-OL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE THEREOF | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | OPRM1 4372/4885OPRD1 2976/4885OPRK1 4078/4885 |
| US-20230310454-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | OPRM1 4432/4885OPRD1 4334/4885OPRK1 3631/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | OPRM1 4659/4885OPRD1 4235/4885OPRK1 4234/4885 |
| US-20210070735-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | OPRM1 4432/4885OPRD1 4334/4885OPRK1 3631/4885 |
| US-20230322732-A1 | RIP1 Inhibitory Compounds and Methods for Making and Using the Same | RIPK1, RIPK2, RIPK3 | OPRM1 4432/4885OPRD1 4334/4885OPRK1 3631/4885 |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | OPRM1 1247/4885OPRD1 1371/4885OPRK1 1177/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | OPRM1 572/4885OPRD1 918/4885OPRK1 536/4885 |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | OPRM1 4432/4885OPRD1 4334/4885OPRK1 3631/4885 |
| US-20210070743-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | OPRM1 4432/4885OPRD1 4334/4885OPRK1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.